Nothing Special   »   [go: up one dir, main page]

KR920700217A - 항 바이러스성 화합물 - Google Patents

항 바이러스성 화합물

Info

Publication number
KR920700217A
KR920700217A KR1019900702612A KR900702612A KR920700217A KR 920700217 A KR920700217 A KR 920700217A KR 1019900702612 A KR1019900702612 A KR 1019900702612A KR 900702612 A KR900702612 A KR 900702612A KR 920700217 A KR920700217 A KR 920700217A
Authority
KR
South Korea
Prior art keywords
formula
compound
phosphate
methylsulfonyl
compound according
Prior art date
Application number
KR1019900702612A
Other languages
English (en)
Inventor
리차드 토마스 워커
알버트 스탠리 존스
Original Assignee
리차드 토마스 워커
알버트 스탠리 존스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898908355A external-priority patent/GB8908355D0/en
Application filed by 리차드 토마스 워커, 알버트 스탠리 존스 filed Critical 리차드 토마스 워커
Publication of KR920700217A publication Critical patent/KR920700217A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

항 바이러스성 화합물
내용없음

Claims (30)

  1. 하기 일반식(Ⅰ)의 화합물 또는 약리학적으로 허용 가능한 이들의 염:
    상기식에서, R1은 지방족 히드로카르빌기이고; Ar은 치환 또는 비치환된 방향족핵이고; X는 －SO2－ 또는 －CO－이고; R2및 R3는 같거나 다를 수 있으며 하기 일반식(a), (b), (c), (d), (e), (f), (g), (h) 또는 (ⅰ)의 부분들이고:
    상기식에서, B는 하기 일반식(A), (G), (C), (H) 또는 (T)의 뉴클레오시드염기의 잔기이며:
    단, R2및 R3가 일반식(a)의 비치환된 부분일 경우, B는 일반식(A), (G), (C) 또는 (H)의 뉴클레오시드염기이다.
  2. 제1항에 있어서, Ar이 치환 또는 비치환된 벤젠고리임을 특징으로 하는 화합물.
  3. 제2항에 있어서, R1X 및 인산염 치환기들의 서로 파라배열을 갖는 것을 특징으로 하는 화합물.
  4. 제1항에 있어서, Ar이 치환된 방향족 핵이어서 화합물(Ⅰ)의 독성에 잘 견디는 대응하는 페놀 R1XArOH로 쉽게 가수분해되는 것을 특징으로 하는 화합물.
  5. 제1항에 있어서, A는 같거나 다를 수 있는 하나 이상의 치환기를 (예로서, 할로겐원자, 플루오로알킬, 알콕시, 플루오로알콕시, 카르보알콕시, 아미노 또는 아미도기)에 의해 치환된 벤젠기임을 특징으로 하는 화합물.
  6. 제1항에 있어서, X는 술포닐기임을 특징으로 하는 화합물.
  7. 제1 내지 제6항중 어느 한항에 있어서, R2및 R3는 각각 일반식(a), (b), (d) 또는 (f)의 부분임을 특징으로 하는 화합물.
  8. 제7항에 있어서, R2및 R3가 각각 일반식(f)의 부분임을 특징으로 하는 화합물.
  9. 제7항에 있어서, R2및 R3가 각각 하기 일반식(ⅰ) 내지 (x)중 어느 하나임을 특징으로 하는 화합물;
  10. 제9항에 있어서, R2및 R3가 각각 일반식(i), (v), (vi) 또는 (ix)임을 특징으로 하는 화합물.
  11. 4－(메틸술포닐)페닐 비스(3´－이지도 티미딘－5´－일)인산염.
  12. 4－(메틸술포닐)페닐 비스(2´, 3´－디데히드로－2´, 3´－디데옥시시티딘－5´－일)인산염
  13. 4－(메틸술포닐)페닐 비스(2´, 3´－디데히드로－2´, 3´－디데옥시시티딘－5´－일)인산염
  14. 4－(메틸술포닐)페닐 비스(2´, 3´－디데옥시아데노신－5´－일)인산염
  15. 4－(메틸술포닐)페닐 비스(2´, 3´－디데히드로－2´, 3´－디데옥시 티미딘－5´－일)인산염
  16. 하기 일반식(Ⅲ)의 포스포로디할로겐화물을 일반식(Ⅱ)의 화합물 또는 R2의 뉴클레오시드염기 내 그룹이 보호된 유도체와 반응시키는 것으로 이루어진 일반식(Ⅰ)의 화합물의 제조방법;
    R1XArOP(O)Y2(Ⅲ)
    R2OH (Ⅱ)
    상기식에서, R1, R2, Ar 및 X는 제1항에 기재된 바와같고, Y는 할로겐원자이다.
  17. 제16항에 있어서, R2내 뉴클레오시드 염기가 아실화에 의해 보호된 시토신임을 특징으로 하는 방법.
  18. 제16 또는 17항에 있어서, 반응이 염기 존재하에 수행되는 것을 특징으로 하는 화합물.
  19. 제18항에 있어서, 염기가 1－메틸이미다졸임을 특징으로 하는 화합물.
  20. R1, Ar, R2및 R3기 제1항에 기재된 바와같은 일반식(Ⅳ): R1SArOP(O)(OR2)(OR3) 또는 일반식(Ⅴ): R1SOArOP(O)(OR2)(OR3)의 화합물을 산화시키는 것을 특징으로 하는, 일반식(Ⅰ)의 화합물의 제조방법.
  21. 제20항에 있어서, 산화가 과(per)산에 의해 수행되는 것을 특징으로 하는 방법.
  22. 일반식(Ⅳ)의 중간체.
  23. 일반식(Ⅴ)의 중간체.
  24. 치료에 사용하기 위한 일반식(Ⅰ)의 화합물.
  25. 사람의 레트로바이러스감염의 치료 또는 예방에 유용한 의약을 제조하기 위한 일반식(Ⅰ)의 화합물 사용.
  26. 아이러스복제를 억제 또는 방해하는데에 유효량의 일반식(Ⅰ)의 화합물을 바이러스로 감염된 객체에 투여하는 것으로 이루어진 사람의 레트로 바이러스 감염의 치료 또는 예방방법.
  27. 바이러스복제를 억제 또는 방해하는 데에 유효량의 일반식(Ⅰ)의 화합물을 가지고서 바이러스로 감염된 혈액을 치료하는 것으로 이루어진 사람의 레트로바이러스감염의 치료 또는 예방방법.
  28. 제26 또는 27항에 있어서, 바이러스가 사람의 면역결핍 바이러스(HIV)임을 특징으로 하는 방법.
  29. 일반식(Ⅰ)의 화합물과 함께 약리학적으로 허용 가능한 이들의 담체를 포함하는 것으로 이루어진, 사람의 레트로바이러스감염의 치료 또는 예방용 제제.
  30. 투여 형태로서의 제29항에 따른 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900702612A 1989-04-13 1990-04-10 항 바이러스성 화합물 KR920700217A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898908355A GB8908355D0 (en) 1988-04-18 1989-04-13 Output apparatus antiviral compounds
GB89083554 1989-04-13
PCT/GB1990/000542 WO1990012023A1 (en) 1989-04-13 1990-04-10 Antiviral compounds

Publications (1)

Publication Number Publication Date
KR920700217A true KR920700217A (ko) 1992-02-19

Family

ID=10654960

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702612A KR920700217A (ko) 1989-04-13 1990-04-10 항 바이러스성 화합물

Country Status (16)

Country Link
EP (1) EP0392791B1 (ko)
JP (1) JPH03505880A (ko)
KR (1) KR920700217A (ko)
CN (1) CN1046531A (ko)
AT (1) ATE125817T1 (ko)
AU (1) AU5407890A (ko)
CA (1) CA2028151A1 (ko)
DE (1) DE69021242T2 (ko)
ES (1) ES2077643T3 (ko)
FI (1) FI906113A0 (ko)
GB (1) GB2230266B (ko)
NZ (1) NZ233197A (ko)
OA (1) OA09553A (ko)
PT (1) PT93743A (ko)
WO (1) WO1990012023A1 (ko)
ZA (1) ZA902784B (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
WO1992011276A1 (en) * 1990-12-18 1992-07-09 Sloan-Kettering Institute For Cancer Research Novel synthesis of 2'-'up' fluorinated 2''-deoxy-arabinofuranosylpurines
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
FR2685331A1 (fr) * 1991-12-12 1993-06-25 Centre Nat Rech Scient Phosphotriesters de la ddu, leur preparation et leur application en therapeutique.
DE59301421D1 (de) * 1992-02-13 1996-02-22 Herbert Prof Dr Schott Amphiphile nucleosidphosphatanaloga
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
JPH10502655A (ja) * 1994-07-15 1998-03-10 グルポ・レペチツト・エス・ピー・エイ ジヌクレオシド−５’，５’−ピロリン酸
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
WO2001012644A1 (en) * 1999-08-17 2001-02-22 Adani, Alexander Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptases and viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA931561A (en) * 1969-03-10 1973-08-07 Syntex Corporation Nucleoside phosphonates, phosphonic acids, phosphonic acid salts, and process for producing same
CA1330794C (en) * 1987-03-27 1994-07-19 Phillip Frost Anti-viral compounds, dosage forms and methods

Also Published As

Publication number Publication date
JPH03505880A (ja) 1991-12-19
ATE125817T1 (de) 1995-08-15
NZ233197A (en) 1991-11-26
FI906113A0 (fi) 1990-12-12
ES2077643T3 (es) 1995-12-01
EP0392791B1 (en) 1995-08-02
WO1990012023A1 (en) 1990-10-18
DE69021242D1 (de) 1995-09-07
EP0392791A1 (en) 1990-10-17
CA2028151A1 (en) 1990-10-14
ZA902784B (en) 1991-12-24
GB2230266B (en) 1992-08-12
CN1046531A (zh) 1990-10-31
DE69021242T2 (de) 1996-01-11
AU5407890A (en) 1990-11-05
GB2230266A (en) 1990-10-17
OA09553A (en) 1993-01-31
GB9008105D0 (en) 1990-06-06
PT93743A (pt) 1990-11-20

Similar Documents

Publication Publication Date Title
KR920700217A (ko) 항 바이러스성 화합물
KR910006293A (ko) 항비루스성 화합물, 이의 제법 및 이를 함유하는 약학적 조성물
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
EP0368640A3 (en) Heterocyclic compounds
EP1035123A4 (en) NEW HETEROCYCLIC COMPOUNDS
ES514877A0 (es) "un procedimiento para preparar derivados de purina".
CA2368615A1 (en) Thiadiazolyl urea or thiourea derivatives for antiviral treatment
KR930006036A (ko) 퓨린 및 피리미딘의 불포화 비환식 포스포네이트 유도체
ES8201966A1 (es) Un procedimiento de produccion de derivados de fenetilamina sulfamoil-sustituidos
KR900003170A (ko) 신규 화합물
ATE74603T1 (de) Derivate von purin, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
AU2866297A (en) Neuraminic acid derivatives, their preparation and their medical use
US3758684A (en) Treating dna virus infections with amino purine derivatives
KR910000734A (ko) 네플라노신 유도체
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
IL88518A (en) 3-(phosphoryl methoxyethoxy) -purine derivatives, their preparation and pharmaceutical compositions containing them
DE69110528D1 (de) Chirale 2-(Phosphonomethoxy)propyl-Guanine als antivirale Agentien.
HU208400B (en) Process for producing pharmaceutical compositions containing benzyl phosphonic acid derivatives of antiviral activity
KR910004621A (ko) 신규 화합물
ES8707254A1 (es) Un procedimiento para preparar un derivado de imidazopiridazina
ES2078139B1 (es) Composiciones antirretrovirales que contienen compuestos iodados.
ZA200309040B (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid